Literature DB >> 32175161

Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.

Gökçen Ömeroğlu Şimşek1, İsmail Ağababaoğlu2, Duygu Dursun1, Selver Özekinci3, Pınar Erçetin1, Hülya Ellidokuz1, Safiye Aktaş1, Duygu Gürel4, İlhan Öztop1, Atila Akkoçlu5.   

Abstract

BACKGROUND: This study aims to evaluate gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma both which have a distinct treatment and prognosis.
METHODS: Between January 2012 and January 2014, 12 newly diagnosed patients with a lung adenocarcinoma, 12 patients with malignant pleural mesothelioma, and eight healthy individuals as the control group were included. After treatment of the fresh samples of lung adenocarcinoma stored at -80°C for ribonucleic acid isolation, and paraffin-embedded tissues of patients with malignant pleural mesothelioma were deparaffinized, complementary deoxyribonucleic acid synthesis and expression of 84 genes associated with deoxyribonucleic acid repair were analyzed via real-time polymerase chain reaction assay. According to the expression of tumor cells, expression of each fold change was calculated.
RESULTS: The BRCA1, BRCA2, CDK7, MLH3, MSH4, NEIL3, SMUG1, UNG, XRCC2, and XRCC4 genes showed more than five-fold higher expression in the patients with lung adenocarcinomas, compared to the control group. The patients with malignant pleural mesothelioma showed a five-fold higher expression in the APEX2, BRCA1, BRCA2, CDK7, MLH1, MLH3, MSH3, MSH4, NEIL3, PARP2, PARP3, PMS1, RAD50, RAD51, RAD51B, RAD51D, RAD52, RPA3, SMUG1, UNG, XPA, XRCC2, and XRCC4 genes, compared to the control group. Comparing malignant pleural mesothelioma with lung adenocarcinoma cases, we found that CDK7, MLH1, TREX1, PRKDC, XPA, PMS1, UNG, and RPA3 genes were overexpressed.
CONCLUSION: Our study results showed differences between expression profiles of deoxyribonucleic acid repair genes in lung adenocarcinoma and malignant pleural mesothelioma cells. Based on our study results, we suggest that TREX1, PRKDC, and PMS1 genes may play a key role in the differential diagnosis of these two entities.
Copyright © 2020, Turkish Society of Cardiovascular Surgery.

Entities:  

Keywords:  Adenocarcinoma; gene expression; lung; malignant; mesothelioma

Year:  2020        PMID: 32175161      PMCID: PMC7067012          DOI: 10.5606/tgkdc.dergisi.2020.17279

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN: 1301-5680            Impact factor:   0.332


  41 in total

Review 1.  Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update.

Authors:  N G Ordóñez
Journal:  Am J Clin Pathol       Date:  1999-07       Impact factor: 2.493

2.  Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.

Authors:  Tetsuo Taniguchi; Sivasundaram Karnan; Takayuki Fukui; Toshihiko Yokoyama; Hiroyuki Tagawa; Kohei Yokoi; Yuichi Ueda; Tetsuya Mitsudomi; Yoshitsugu Horio; Toyoaki Hida; Yasushi Yatabe; Masao Seto; Yoshitaka Sekido
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

3.  Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.

Authors:  H Osada; Y Tatematsu; A Masuda; T Saito; M Sugiyama; K Yanagisawa; T Takahashi
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.

Authors:  Gretchen V Gee; Devin C Koestler; Brock C Christensen; David J Sugarbaker; Donatella Ugolini; Giovanni P Ivaldi; Murray B Resnick; E Andres Houseman; Karl T Kelsey; Carmen J Marsit
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

5.  Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma.

Authors:  Brock C Christensen; E Andres Houseman; Graham M Poage; John J Godleski; Raphael Bueno; David J Sugarbaker; John K Wiencke; Heather H Nelson; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

6.  The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.

Authors:  Peter B Illei; Marc Ladanyi; Valerie W Rusch; Maureen F Zakowski
Journal:  Cancer       Date:  2003-02-25       Impact factor: 6.860

Review 7.  Chromosomal imbalances in human lung cancer.

Authors:  Binaifer R Balsara; Joseph R Testa
Journal:  Oncogene       Date:  2002-10-07       Impact factor: 9.867

8.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Authors:  Young Lim Choi; Kengo Takeuchi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Toru Hamada; Hidenori Haruta; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Toshihide Ueno; Shuji Takada; Yoshihiro Yamashita; Yukihiko Sugiyama; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

9.  Proteomic patterns of tumour subsets in non-small-cell lung cancer.

Authors:  Kiyoshi Yanagisawa; Yu Shyr; Baogang J Xu; Pierre P Massion; Paul H Larsen; Bill C White; John R Roberts; Mary Edgerton; Adriana Gonzalez; Sorena Nadaf; Jason H Moore; Richard M Caprioli; David P Carbone
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

10.  Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma.

Authors:  A G Knudson; H W Hethcote; B W Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

View more
  1 in total

Review 1.  Function and molecular mechanisms of APE2 in genome and epigenome integrity.

Authors:  Yunfeng Lin; Anne McMahon; Garrett Driscoll; Sharon Bullock; Jianjun Zhao; Shan Yan
Journal:  Mutat Res Rev Mutat Res       Date:  2020-11-16       Impact factor: 5.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.